Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 11,600 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Arrowhead Pharmaceuticals Trading Down 2.2%

Shares of Arrowhead Pharmaceuticals stock traded down $1.94 on Thursday, hitting $87.47. 896,837 shares of the company’s stock traded hands, compared to its average volume of 2,359,317. Arrowhead Pharmaceuticals, Inc. has a one year low of $19.82 and a one year high of $95.49. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The company has a fifty day moving average of $82.33 and a two-hundred day moving average of $72.64. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of -38.88 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same quarter in the previous year, the firm posted ($1.26) earnings per share. The company’s revenue for the quarter was up 171.0% compared to the same quarter last year. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current year.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ARWR. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. Optiver Holding B.V. grew its position in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares during the period. Versant Capital Management Inc increased its holdings in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after buying an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC raised its position in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the subject of a number of research analyst reports. B. Riley Financial boosted their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Royal Bank Of Canada lifted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday. Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective on the stock. Finally, Piper Sandler reissued an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $97.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.